Lenalidomide in Kaposi Disease Associated With HIV Infection
Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Lenakap : This multicenter, non randomized (single arm), open, phase II study aims to
evaluated the efficacy of Lenalidomide in HIV-associated kaposi disease. Patients will be
followed for 48 weeks. Measurement of primary endpoint will be at 24 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis